Articles by Richard Riedel, MD
Unmet Needs and the Future of Desmoid Tumor Management
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Experts discuss the unmet needs in desmoid tumor management, emphasizing personalized treatment, quality of life, and the importance of specialized care.
Optimizing Patient Care and the Potential of Artificial Intelligence
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Experts discuss the challenges of diagnosing rare diseases and the potential role of AI in improving patient management and treatment outcomes.
Additional Clinical Considerations for Desmoid Tumors
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Explore the integration of Desmoid Tumor Working Group recommendations with NCCN guidelines and the importance of shared decision-making in patient care.
Insurance Coverage and Patient Education
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.
Dose Reducing and Sequencing Therapies in Desmoid Tumors
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.
Examining a Novel FDA-approved Therapy in Desmoid Tumors
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D FDA approval of Nirogacistat for desmoid tumors highlights improved survival rates, quality of life, and manageable side effects for patients.
Novel Pharmacotherapies and NCCN Guideline Recommendations
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Explore the evolving landscape of desmoid tumor treatments, including chemotherapy, tyrosine kinase inhibitors, and emerging clinical trials.
Surgery, Cryotherapy, and Radiotherapy for Desmoid Tumors
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Explore the evolving landscape of desmoid tumor treatments, highlighting surgery, cryotherapy, and radiotherapy for effective patient care.
When to Observe Desmoid Tumors
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Experts discuss the complexities of observing desmoid tumors, weighing the benefits of active surveillance against the need for immediate treatment.
The Burden and Unmet Needs Associated with Desmoid Tumors
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Patients with desmoid tumors face significant clinical and economic burdens, impacting their quality of life and leading to ongoing treatment challenges.
The Role of Molecular Biomarkers in Diagnosing Desmoid Tumors
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Explore the critical role of biomarkers in diagnosing desmoid tumors and the importance of early detection for patient quality of life.
Exploring the Heterogeneous Nature of Desmoid Tumors
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Exploring the Heterogeneous Nature of Desmoid Tumors
Key Background Information on Desmoid Tumors
ByScott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Mrinal Gounder, MD,Gina D'Amato, MD,Ryan Haumschild, PharmD, MS, MBA,Richard Riedel, MD,Alexander Lazar, M.D., Ph.D Key Background Information on Desmoid Tumors
